Business Wire

Landmark Clinical Study Validates Patch-Based Onera Home-Polysomnography System in One of the Largest Sleep Diagnostic Trials of the Decade

13.1.2025 14:00:00 CET | Business Wire | Press release

Share

Study demonstrates comparable performance between wireless, patch-based Onera Sleep Test System and in-lab polysomnography for sleep staging and respiratory event detection.

Onera Health, a leader in transforming sleep medicine and remote monitoring, today announced the publication of a multicenter validation study of its Onera Sleep Test System (STS) in the Journal of Clinical Sleep Medicine, the official journal of the American Academy of Sleep Medicine. The study demonstrated that the patch-based Onera STS home-polysomnography (hPSG) performs comparably to gold-standard in-lab polysomnography (PSG) for both sleep staging and respiratory event detection.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113111691/en/

A woman is conducting a sleep test (polysomnography) using the patch-based Onera STS hPSG system. (Photo: Business Wire)

The international multicenter study was managed by an independent Clinical Research Organization and involved the analysis of 206 participants across seven clinical sites in Germany and a US-based core laboratory at Johns Hopkins University. The study found high concordance between the Onera STS and traditional PSG across essential sleep variables and key respiratory parameters, as well as substantial epoch-by-epoch agreement in sleep staging and comparable inter-scorer reliability between the two systems, which is essential for physicians to make accurate diagnoses and treatment decisions in sleep medicine.

"Our rigorous multicenter validation study provides robust evidence that the Onera Sleep Test System performs comparably to traditional in-lab polysomnography for sleep staging and respiratory event detection," said Dr. Christian Viniol, MD, Ph. D, lead author and Head of Sleep Medicine at University Hospital Marburg, Germany. "This validation is crucial as we face increasing demand for sleep studies alongside increasing resource constraints. The proven accuracy of Onera’s product will significantly improve access to comprehensive sleep diagnostics, potentially transforming our approach to diagnosing and treating sleep disorders on a larger scale."

"We are thrilled with the successful completion of this comprehensive validation study," said Ruben de Francisco, Founder and CEO of Onera Health. "This validation is a critical milestone in our mission to make the gold-standard sleep test, polysomnography or PSG, available at the patient’s home. The results clearly demonstrate that our innovative, patch-based technology can deliver the level of accuracy needed for a comprehensive hPSG sleep test, with an accuracy that is equivalent to that of traditional in-lab PSG."

"These results represent an important milestone in our journey toward more accessible and personalized sleep medicine. The Onera technology enables high-quality sleep assessment in the patient's natural environment, opening new possibilities for longitudinal monitoring and improved assessment of treatment outcomes. This capability may fundamentally transform the future of sleep disorder diagnosis and treatment evaluation in the future," added Dr. David P. White, Professor of Medicine, Part Time at Harvard Medical School, Boston, United States, and Member of the Medical Advisory Board at Onera Health.

The wireless, patch-based Onera STS hPSG addresses critical challenges in sleep medicine by providing a viable alternative to traditional in-lab polysomnography. Its comparable performance in sleep staging and respiratory event detection, coupled with simplified application, significantly increases access to high-quality, comprehensive sleep assessments.

This landmark validation study is part of Onera Health's comprehensive clinical evidence generation program, demonstrating the commitment to rigorous scientific validation of Onera’s technology. Additional studies are currently ongoing across multiple centers and healthcare settings, which will further validate the clinical utility and real-world impact of Onera’s home Polysomnography solution. This evidence generation strategy reflects Onera’s dedication to advancing sleep medicine through high-quality clinical research.

The study, entitled 'Clinical validation of a wireless patch-based polysomnography system', is published in the Journal of Clinical Sleep Medicine and can be accessed online at https://jcsm.aasm.org/doi/10.5664/jcsm.11524.

About Onera

Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the U.S. For more information, go to onerahealth.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250113111691/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release

New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights

Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release

From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge

RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release

A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo

Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying1.4.2026 03:00:00 CEST | Press release

Online sales outpace in-store by 6x as digital-first and AI-influenced commerce accelerates globally NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets. As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem. Key findings from the State of Beauty 2026 report: Global beauty sales grew 10% year-over-year, driven by strong digital acceleration E-commerce is growing 6x faster than in-store sales,

bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release

Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye